-
1.发明授权
公开(公告)号：EP0682526B1
公开(公告)日：2002-09-04
申请号：EP94909571.5
申请日：1994-02-08
发明人： LEVIN, James L. , REGAL, Jean F. , TOTH, Carol A.
CPC分类号： A61K9/0078 , A61K38/00 , C07K14/705
摘要： The present invention relates to formulations for pulmonary administration by inhalation that comprise a complement inhibitory protein, and uses thereof in the prophylactic or therapeutic treatment of diseases or disorders involving complement, especially diseases or disorders of the lung. In particular, the proteins are complement receptors of fragments thereof or soluble members of the complement receptor family that contain the conserved SCR motif and that are able to inhibit complement activity. More particularly the present invention relates to the direct treatment of certain complement related lung disorders by administering complement receptor proteins via the pulmonary route, in particular, direct delivery to the lungs of a complement receptor protein by aerosolization and subsequent inhalation. The invention also relates to use of a complement inhibitory protein to treat bronchoconstriction or anaphylaxis, or both.
-
2.发明公开PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS 失效sCR1的UNDANDEREN行政补体抑制剂关于长。
公开(公告)号：EP0682526A1
公开(公告)日：1995-11-22
申请号：EP94909571.0
申请日：1994-02-08
发明人： LEVIN, James L. , REGAL, Jean F. , TOTH, Carol A.
IPC分类号： C12N15 , A61K9 , A61K38 , A61P9 , A61P11 , A61P25 , A61P29 , A61P31 , A61P37 , C07K14 , C12N5 , C12P21 , C12R1
CPC分类号： A61K9/0078 , A61K38/00 , C07K14/705
摘要： The present invention relates to formulations for pulmonary administration by inhalation that comprise a complement inhibitory protein, and uses thereof in the prophylactic or therapeutic treatment of diseases or disorders involving complement, especially diseases or disorders of the lung. In particular, the proteins are complement receptors of fragments thereof or soluble members of the complement receptor family that contain the conserved SCR motif and that are able to inhibit complement activity. More particularly the present invention relates to the direct treatment of certain complement related lung disorders by administering complement receptor proteins via the pulmonary route, in particular, direct delivery to the lungs of a complement receptor protein by aerosolization and subsequent inhalation. The invention also relates to use of a complement inhibitory protein to treat bronchoconstriction or anaphylaxis, or both.
-
搜索结果
2 条记录 (耗时 0.012 秒)
